🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the fight against superbug strains of the pathogen, according to scientists.

An International Challenge

Cases of gonorrhoea are on the rise around the world, with estimates suggesting in excess of 82 million instances per year. Notably increased rates are seen in Africa and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune advancement in the context of rising global incidence, escalating drug resistance and the extremely scarce available drugs currently available.”

Health officials are increasingly worried about the increase in antibiotic-resistant strains. The World Health Organization has classified it as a "priority pathogen". Recent surveillance revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Receive Approval

One new antibiotic, marketed under the name Nuzolvence, was approved by the American regulatory agency in recent days for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Researchers believe that specific application of this new drug will help slow the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This medication, which is also used to treat urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin emerged from a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to bring it to fruition.

“This approval signifies a significant shift in the therapy of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Clinical Trial Outcomes and Worldwide Availability

As per results published in a prominent scientific publication, zoliflodacin eradicated more than 90% of uncomplicated infections. This puts it on an similar efficacy with the current standard treatment, which uses two antibiotics. The study enrolled hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the authority to license and sell the drug in a wide range of developing nations.

Medical professionals treating patients have expressed hope. The availability of a one-pill regimen such as this is seen as a "revolutionary step" for managing the epidemic. This is considered crucial to reduce the burden of the disease for people and to halt the transmission of highly drug-resistant gonorrhoea around the world.